用批判性种族理论理解黑人系统性红斑狼疮患者参与临床试验:患者与照护者质性研究
该质性研究在芝加哥和波士顿开展4个焦点小组,共31名黑人参与者(20例SLE患者、11名照护者),以批判性种族理论探讨racism对黑人SLE患者临床试验代表性不足的影响。分析揭示与racism相关的不信任、对安慰剂分组的担忧、严格排除标准和SLE相关顾虑阻碍参与;医生与权威机构推荐、利他动机和文化敏感的宣传可促进参与。
要点
- racism相关不信任、安慰剂担忧和严格排除标准是黑人SLE患者参与试验的主要障碍。
- 医生及权威机构推荐、利他动机和文化敏感宣传可提升黑人SLE患者试验参与意愿。
- 社区-学术合作可能有助于建立信任并减少对不当对待的恐惧。
核心结论
- 改善黑人SLE患者临床试验参与应重新设计试验信息的呈现与传播方式,并重新评估限制参与的障碍。
- 研究者必须承认并回应医疗保健中的种族偏见,社区-学术合作可能有助于建立信任并减少对不当对待的恐惧。
研究设计与样本
- 在芝加哥和波士顿开展焦点小组的质性研究,纳入年龄≥18岁的黑人SLE成人及其照护者。
- 共4个焦点小组、31名参与者,其中20例为SLE患者、11名为照护者;全部为黑人,90%为女性,平均年龄54岁。
- 焦点小组内容逐字转录并进行主题分析,以批判性种族理论为框架。
主要发现
- 阻碍试验参与的主题包括与racism相关的不信任、对安慰剂分组的担忧、严格的研究排除标准以及SLE相关顾虑。
- 促进试验参与的因素包括医生和信誉良好机构的推荐、帮助更大利益的愿望以及文化敏感的宣传。
临床怎么用
- 向黑人SLE患者传播试验信息时应采用文化敏感的方式,并借助医生和信誉良好机构的推荐。
- 设计试验时应重新评估排除标准等可能限制黑人SLE患者参与的障碍。
- 可通过社区-学术合作建立信任,回应racism相关不信任和对不当对待的恐惧。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Black patients with systemic lupus erythematous (SLE) experience greater disease incidence and severity than White patients, and yet they are underrepresented in SLE clinical trials. We applied Critical Race Theory to qualitatively explore the influence of racism on the underrepresentation of Black patients in SLE clinical trials and to develop a framework for future intervention. METHODS: We conducted focus group sessions in Chicago and Boston with Black adults (ages ≥18 years) with SLE and their caregivers. We queried the participants about their knowledge regarding clinical trials, factors that might motivate or hinder trial participation, and how race and experiences of racism might impact clinical trial participation. Focus group responses were transcribed verbatim and analyzed thematically. RESULTS: We held 4 focus groups (n = 31 participants); 20 participants had SLE, and 11 were caregivers. All participants were Black, 90% were women, and the mean age was 54 years. Qualitative analyses revealed several themes that negatively impact trial participation, including mistrust related to racism, concerns about assignment to placebo groups, strict study exclusion criteria, and SLE-related concerns. Factors that motivated trial participation included recommendations from physicians and reputable institutions, a desire to help the greater good, and culturally sensitive marketing of trials. CONCLUSION: Actions to improve clinical trial participation among Black individuals should focus on reframing how trial information is presented and disseminated and on reevaluating barriers that may restrict trial participation. Additionally, researchers must acknowledge and respond to the presence of racial bias in health care. Community-academic partnerships may help build trust and reduce fears of mistreatment among Black individuals with SLE.
引用
- Sneed RS, Mason M, Williams JN, et al. Using Critical Race Theory to Understand Trial Participation Among Black Individuals With Systemic Lupus Erythematosus: A Qualitative Study of Patients and Caregivers. Arthritis Care Res (Hoboken). 2021. PMID: 33973413. doi:10.1002/acr.24635
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。